Solara Active Pharma Sciences Limited has successfully completed its postal ballot process for the appointment of Mr. Mohanraj Sanjeevi (DIN: 08420411) as Whole-time Director (Executive Director). The company formally communicated the voting results to BSE Limited and National Stock Exchange of India Limited on March 10, 2026, pursuant to Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Overwhelming Shareholder Support

The postal ballot results demonstrate exceptional shareholder confidence in the appointment, with the special resolution passed with requisite majority on March 06, 2026.

Category-wise Voting Pattern

The resolution received unanimous support from promoter and institutional categories, with minimal dissent from public non-institutional shareholders.

Official Compliance and Documentation

The scrutinizer's report was prepared by Preetnam Hebbar & Co., Company Secretaries, confirming the validity of the postal ballot process conducted entirely through remote e-voting in compliance with MCA General Circulars.

Appointment Details and Remuneration

Mr. Mohanraj Sanjeevi has been appointed as Whole-time Director for a period of three years, effective from January 01, 2026, to December 31, 2028, with a comprehensive remuneration package.

Additional benefits include insurance and social security benefits, encashment of un-availed earned leave, business travel expense reimbursements, company-sponsored car and driver for business purposes, ESOP grants, and corporate credit card facility as approved by the Board.

Voting Process Timeline

The postal ballot was conducted entirely through remote e-voting in compliance with regulatory requirements, with Central Depository Services (India) Limited providing the e-voting platform.

Solara Active Pharma Sciences Limited conducted its Q3FY26 earnings conference call on February 6, 2026, providing detailed insights into the company's strategic transformation amid challenging market conditions. The management outlined comprehensive plans to address structural issues in the ibuprofen business while strengthening its high-margin growth API portfolio.

Strategic Business Evaluation and Advisory Engagement

Founder and Non-Executive Director Arun Kumar announced the Board's decision to engage strategic advisors to evaluate options for the ibuprofen business. The company will also reassess the previously announced scheme for the CRAMS business split, with comprehensive recommendations expected by Q4FY26 results.

Business Segment Performance Analysis

The management provided unprecedented transparency by separately disclosing performance metrics for both business segments, highlighting the stark contrast between the struggling ibuprofen base business and the thriving growth API portfolio.

Growth API Business Metrics:

Base Ibuprofen API Business Challenges:

Management Commentary on Market Dynamics

Managing Director Sandeep Rao emphasized that the growth API business demonstrates "class-leading" numbers with superior profitability. The company continues serving marquee customers in the ibuprofen segment despite persistent pricing pressures and excess industry capacity.

Arun Kumar highlighted the structural challenges facing the ibuprofen business, noting that Solara's 20-year-old manufacturing processes cannot be easily changed due to regulatory constraints from long-standing big pharma customers. The company sells ibuprofen at 15-17% premium to competition but still faces margin pressures.

Financial Performance and Debt Reduction Progress

CFO Sarat Kumar reported continued progress in debt reduction initiatives:

Facility Optimization and R&D Strategy

The company outlined plans to revive the mothballed Vizag facility by converting it from a single-product ibuprofen plant to a multipurpose facility. One block will be converted for multipurpose API manufacturing while another will focus on high potent APIs.

The management confirmed increased R&D investments and new talent acquisition to support the facility conversion and feed the growth API pipeline. The company has been successfully reviving dormant Drug Master Files (DMFs) to support its small volume, high-margin API strategy.

Corporate Actions and Future Roadmap

The Board decided to delay all previously announced corporate actions pending completion of the strategic review. This includes reassessing the CRAMS business split, which was initially planned as a balance sheet optimization measure.

Arun Kumar indicated that given the strong cash generation from the non-ibuprofen business, an integrated structure combining CDMO and complex APIs under one entity may create more value than separation.

Operational Highlights and Market Position

The company maintains its strong position in developed markets, contributing 75% of overall sales. Despite facing headwinds in the commodity ibuprofen segment, the derivatives business remains profitable and forms part of the growth portfolio.

Management expressed confidence in the resilient operating model, robust compliance framework, and diversified portfolio across key markets, positioning the company for sustainable growth once structural issues are addressed.